Use Insomnia: Treatment of insomnia characterized by difficulty with sleep onset
Off-Label Use: Delirium (prevention), ICU related
#仿單變更2020

Hypnotic, Miscellaneous; Melatonin Receptor Agonist

Half-life elimination: Ramelteon: 1 to 2.6 hours Excretion: Primarily as metabolites: Urine (84%); feces (4%)

History of angioedema with previous ramelteon therapy (do not rechallenge); concurrent use with fluvoxamine

C
Adverse events were observed in some animal reproduction studies.<20201207>

It is not known if ramelteon is excreted in breast milk. The manufacturer recommends that caution be used when administering ramelteon to breastfeeding women.
Monitor infants exposed to ramelteon via breast milk for somnolence and feeding problems. <20201207>

Dizziness , somnolence , fatigue, insomnia worsened ,Nausea

Insomnia: Oral: 8 mg once daily administered within 30 minutes of bedtime. Maximum dose: 8 mg/day. Delirium (prevention), ICU related (off-label use): 8 mg once daily at bedtime (Hatta 2014). Additional trials may be necessary to further define the role of ramelteon in the prevention of ICU delirium.

Safety and efficacy not established in pediatric patients

No dosage adjustment necessary.

Mild impairment: There are no dosage adjustments provided in the manufacturer's labeling. Moderate impairment: There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Severe impairment: Use is not recommended.

Store at 25 degrees C.